{"DataElement":{"publicId":"7433917","version":"1","preferredName":"Clinical Study Therapeutic Procedure Stratification Type","preferredDefinition":"Information related to the type of therapeutic procedure stratification in this clinical trial.","longName":"7433909v1.0:7433898v1.0","context":"Alliance","contextVersion":"1","DataElementConcept":{"publicId":"7433909","version":"1","preferredName":"Clinical Study Therapeutic Procedure Stratification","preferredDefinition":"Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, study of mechanisms of human diseases, therapy, clinical trials, epidemiologic, behavior, and health services research._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._The process of classifying patients into a sequence of grades or ranks as part of the randomization process or for purposes of data analysis.","longName":"2430995v1.0:7433907v1.0","context":"Alliance","contextVersion":"1","ObjectClass":{"publicId":"2430995","version":"1","preferredName":"Study","preferredDefinition":"A type of research study that tests how well new medical treatments or other interventions work in people.  Such studies test new methods of screening, prevention, diagnosis, or treatment of a disease.  The study may be carried out in a clinic or other medical facility.  Also called a clinical trial.","longName":"C15206","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Study","conceptCode":"C15206","definition":"Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, study of mechanisms of human diseases, therapy, clinical trials, epidemiologic, behavior, and health services research.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"05D7809E-DF10-22B4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-18","modifiedBy":"ONEDATA","dateModified":"2005-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7433907","version":"1","preferredName":"Therapeutic Procedure Stratification","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.:The process of classifying patients into a sequence of grades or ranks as part of the randomization process or for purposes of data analysis.","longName":"C49236:C25689","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Stratification","conceptCode":"C25689","definition":"The process of classifying patients into a sequence of grades or ranks as part of the randomization process or for purposes of data analysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B0110477-6557-3C99-E053-4EBD850A028D","latestVersionIndicator":"Yes","beginDate":"2020-09-24","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-09-24","modifiedBy":"ONEDATA","dateModified":"2020-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B0110477-6568-3C99-E053-4EBD850A028D","latestVersionIndicator":"Yes","beginDate":"2020-09-24","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-09-24","modifiedBy":"MORENOC","dateModified":"2021-03-29","changeDescription":"3/29/2021: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7433898","version":"1","preferredName":"Clinical Study Therapeutic Procedure Stratification Type","preferredDefinition":"The type of therapeutic procedure stratification in this clinical trial.","longName":"7433898v1.0","context":"Alliance","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Concurrent ICI plus chemotherapy combination","valueDescription":"Concurrent Immune Checkpoint Inhibitor With Chemotherapy Combination Drug Therapy","ValueMeaning":{"publicId":"7433899","version":"1","preferredName":"Concurrent Immune Checkpoint Inhibitor With Chemotherapy Combination Drug Therapy","longName":"7433899","preferredDefinition":"Occurring or operating at the same time.: An agent that inhibits any of the immune checkpoint inhibitory proteins.: Used to indicate the presence of something or someone.: The use of synthetic or naturally-occurring chemicals for the treatment of diseases.: Drug therapy with two or more drugs given separately or together for a combined effect.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Concurrent","conceptCode":"C25456","definition":"Occurring or operating at the same time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Immune Checkpoint Inhibitor","conceptCode":"C143250","definition":"An agent that inhibits any of the immune checkpoint inhibitory proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"With","conceptCode":"C62355","definition":"Used to indicate the presence of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Combination Drug Therapy","conceptCode":"C16144","definition":"Drug therapy with two or more drugs given separately or together for a combined effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B01061E6-10C8-3C87-E053-4EBD850A6186","latestVersionIndicator":"Yes","beginDate":"2020-09-24","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-09-24","modifiedBy":"ONEDATA","dateModified":"2020-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B01061E6-10E1-3C87-E053-4EBD850A6186","beginDate":"2020-09-24","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-09-24","modifiedBy":"ONEDATA","dateModified":"2020-09-24","deletedIndicator":"No"},{"value":"Chemotherapy followed by ICI maintenance","valueDescription":"Chemotherapy Next Immune Checkpoint Inhibitor Maintenance Therapy","ValueMeaning":{"publicId":"7433900","version":"1","preferredName":"Chemotherapy Next Immune Checkpoint Inhibitor Maintenance Therapy","longName":"7433900","preferredDefinition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.: Subsequent; immediately following in time or order.: An agent that inhibits any of the immune checkpoint inhibitory proteins.: Continuation of treatment for an extended period of time to prevent relapse.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Next","conceptCode":"C53286","definition":"Subsequent; immediately following in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Immune Checkpoint Inhibitor","conceptCode":"C143250","definition":"An agent that inhibits any of the immune checkpoint inhibitory proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Maintenance Therapy","conceptCode":"C15688","definition":"Continuation of treatment for an extended period of time to prevent relapse.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B01061E6-10F0-3C87-E053-4EBD850A6186","latestVersionIndicator":"Yes","beginDate":"2020-09-24","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-09-24","modifiedBy":"ONEDATA","dateModified":"2020-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B01061E6-1109-3C87-E053-4EBD850A6186","beginDate":"2020-09-24","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-09-24","modifiedBy":"ONEDATA","dateModified":"2020-09-24","deletedIndicator":"No"},{"value":"ICI monotherapy first-line","valueDescription":"Immune Checkpoint Inhibitor Single Agent Therapy First-Line Therapy","ValueMeaning":{"publicId":"7433901","version":"1","preferredName":"Immune Checkpoint Inhibitor Single Agent Therapy First-Line Therapy","longName":"7433901","preferredDefinition":"An agent that inhibits any of the immune checkpoint inhibitory proteins.: Pharmacotherapy consisting of a single agent.: The preferred standard treatment for a particular condition.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune Checkpoint Inhibitor","conceptCode":"C143250","definition":"An agent that inhibits any of the immune checkpoint inhibitory proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Single Agent Therapy","conceptCode":"C157514","definition":"Pharmacotherapy consisting of a single agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"First-Line Therapy","conceptCode":"C45792","definition":"The preferred standard treatment for a particular condition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B01061E6-1117-3C87-E053-4EBD850A6186","latestVersionIndicator":"Yes","beginDate":"2020-09-24","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-09-24","modifiedBy":"ONEDATA","dateModified":"2020-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B01061E6-1130-3C87-E053-4EBD850A6186","beginDate":"2020-09-24","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-09-24","modifiedBy":"ONEDATA","dateModified":"2020-09-24","deletedIndicator":"No"},{"value":"ICI monotherapy second-line and beyond","valueDescription":"Immune Checkpoint Inhibitor Single Agent Therapy Second-Line Therapy And Beyond","ValueMeaning":{"publicId":"7433902","version":"1","preferredName":"Immune Checkpoint Inhibitor Single Agent Therapy Second-Line Therapy And Beyond","longName":"7433902","preferredDefinition":"An agent that inhibits any of the immune checkpoint inhibitory proteins.: Pharmacotherapy consisting of a single agent.: The second preferred therapy for a particular condition, used after first-line treatment fails or if a person cannot tolerate first-line drugs.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: Past a place or outside an area.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune Checkpoint Inhibitor","conceptCode":"C143250","definition":"An agent that inhibits any of the immune checkpoint inhibitory proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Single Agent Therapy","conceptCode":"C157514","definition":"Pharmacotherapy consisting of a single agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Second-Line Therapy","conceptCode":"C54350","definition":"The second preferred therapy for a particular condition, used after first-line treatment fails or if a person cannot tolerate first-line drugs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Beyond","conceptCode":"C151408","definition":"Past a place or outside an area.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B01061E6-1140-3C87-E053-4EBD850A6186","latestVersionIndicator":"Yes","beginDate":"2020-09-24","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-09-24","modifiedBy":"ONEDATA","dateModified":"2020-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B01061E6-1159-3C87-E053-4EBD850A6186","beginDate":"2020-09-24","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-09-24","modifiedBy":"ONEDATA","dateModified":"2020-09-24","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B01061E6-10AB-3C87-E053-4EBD850A6186","latestVersionIndicator":"Yes","beginDate":"2020-09-24","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-09-24","modifiedBy":"MORENOC","dateModified":"2021-03-29","changeDescription":"3/29/2021: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Line and type of therapy","type":"Preferred Question Text","description":"Line and type of therapy","url":null,"context":"Alliance"}],"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B01061E6-1165-3C87-E053-4EBD850A6186","latestVersionIndicator":"Yes","beginDate":"2020-09-24","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-09-24","modifiedBy":"MORENOC","dateModified":"2021-03-29","changeDescription":"3/29/2021: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}